Allied Biomedical Research Institute | Miami, FL

Research site

(Unclaimed)

Location

7100 Southwest 47th street, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

KarXT

Gantenerumab

Allopurinol

TRx0237

Pomotrelvir

ACT-132577

Fasinumab

PBI-0451

Piromelatine

18F

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 25 total trials

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Al...

Enrolling

Psychosis Associated With Alzheimer's Disease

Drug: Placebo

Drug: KarXT

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting

Osteoarthritis

Drug: RTX-GRT7039

Drug: Placebo

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling

Agitation

Alzheimer's Type Dementia

Drug: Masupirdine 100 mg

Drug: Masupirdine 50 mg

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026 or CN012-0027. Sub...

Invitation-only

Psychosis Associated With Alzheimer's Disease

Drug: KarXT

PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI-0451(Pomotrelvir)...

Active, not recruiting

COVID-19

Drug: PBI-0451 (Pomotrelvir)

Drug: Placebo

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: AR1001

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting

Alzheimer's Disease

Drug: Piromelatine 20 mg

Drug: Placebo

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (EURELIA2)

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling

Hyperuricemia

Tophi

Drug: Tigulixostat

Drug: Placebo